The liver imaging and reporting data system treatment response algorithm (LIRADS TRA) for CT and MRI has been used to predict residual viable tumor after treatment with yttrium-90 (Y-90). This single-center cohort of 20 patients were reviewed using the LIRADS TRA assessing residual viable tumor following Y-90 therapy. Pathology of subsequent liver explants was the reference standard. The LIRADS TRA predicted positive treatment effect (nonviable): NPV 82.4% (95% CI 0.47-1.55), accuracy 75% (72.0-89.4). The results of this preliminary study will need further validation in a larger, similar, pathologic-confirmed cohort.
This abstract and the presentation materials are available to members only; a login is required.